
Ahmed Zayed Obeidat, MD, PhD
Associate Professor
Location
- Neuroscience Center – Specialty Clinics
- 900 N. 92nd St.
- Milwaukee, WI 53226
Specialties
- Neurology
New & Established Patients Call
The key to success is teamwork. We will work together with you and your loved ones to fight MS and other neuroimmunological diseases in a personalized and comprehensive approach to best fit your needs and expectations. Remember, you are the center of our care and persistence is the key to success!
Overview
Diseases and Conditions
- Multiple Sclerosis (MS)
- Stiff Person Syndrome (SPS)
- Neuromyelitis Optica (NMO)
- Autoimmune Diseases of the Central Nervous System
- Autoimmune Encephalitis
- Neurosarcoidosis
- Anti-MOG Disease
Treatments and Services
- Neuro-Immunology
- Oral/injectable/infused and Symptomatic Therapies for Multiple Sclerosis
- Virtual Visit
Patients Ages Seen
- Adult
- Senior
Languages
- English
- Arabic
Hospital Affiliations
- Froedtert Hospital – Milwaukee
Board Certifications
- Neurology
Clinic Locations
Neuroscience Center – Specialty Clinics
- 900 N. 92nd St.
- Milwaukee, WI 53226
- (414) 805-5400
- Get Directions

Biography
Dr. Obeidat works with adults in diagnosing, treating and managing Multiple Sclerosis and Immune Disorders of the Central Nervous System. He received his medical degree with honors from the Jordan University of Science and Technology in 2008. He then joined the graduate program in neuroscience and physiology at Wright State University (WSU) in Dayton, Ohio where he received a PhD in Neuroscience and Physiology in 2013. He completed his neurology residency at the University of Cincinnati in 2017 as well as fellowship training in Demyelinating Diseases and Neuroimmunology, also from the University of Cincinnati, in 2018. Dr. Obeidat is an advocate for medical humanities and believes in the power of patient stories in shaping a successful, and a long-lasting patient-doctor relationship. In his free time, he enjoys reading and writing personal reflections and narrative medicine in its various forms.
Education and Training
Doctor of Philosophy in Biomedical Sciences (Neuroscience and Physiology) - Wright State University - Dayton, OH (2013)
Fellowship in Neuroimmunology and Multiple Sclerosis - University of Cincinnati - Cincinnati, OH (2017-2018)
Residency in Neurology - University of Cincinnati - Cincinnati, OH (2014-2017)
Publications
-
(Gurski CJ, Hajiyeva Z, Veltri AJ, Fenton K, O'Dell S, Obeidat AZ, Dittel BN.) J Neuroimmunol. 2025 Feb 15;399:578519 PMID: 39731832 SCOPUS ID: 2-s2.0-85213253349 12/29/2024
-
(Gurski CJ, Hajiyeva Z, Veltri AJ, Fenton K, O'Dell S, Obeidat AZ, Dittel BN.) J Neuroimmunol. 2025 Feb 15;399:578502 PMID: 39643951 SCOPUS ID: 2-s2.0-85211034715 12/07/2024
-
Clinical decision support improves autoimmune/paraneoplastic antibody panel utilization.
(Nerenz RD, Hooshmand SI, Jackowiak E, Shirilla D, Yang Y, Yang K, Obeidat AZ.) Am J Clin Pathol. 2025 Jan 28;163(1):109-120 PMID: 39255415 SCOPUS ID: 2-s2.0-85217064358 09/10/2024
-
(Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators.) Lancet Neurol. 2024 Nov;23(11):1119-1132 PMID: 39307151 09/23/2024
-
JC virus or extended interval dosing? More data are needed.
(Obeidat AZ.) Mult Scler. 2024 Nov;30(13):1698 PMID: 39240139 SCOPUS ID: 2-s2.0-85203433093 09/06/2024
-
(Porwal MH, Razzak AN, Kumar V, Obeidat AZ, Sharma U.) Epilepsy Res. 2024 Jul;203:107382 PMID: 38761467 SCOPUS ID: 2-s2.0-85193210316 05/19/2024
-
Impact of neuromyelitis optica spectrum disorder on employment and income in the United States.
(Hjerthen IG, Trápaga Hacker C, Meador W, Obeidat AZ, Horta L, Mateen FJ.) Ann Clin Transl Neurol. 2024 Apr;11(4):1011-1020 PMID: 38374778 PMCID: PMC11021617 SCOPUS ID: 2-s2.0-85186173891 02/20/2024
-
Increased healthcare utilization in the year before multiple sclerosis diagnosis.
(Razzak AN, Hernandez RS, Salter A, Obeidat AZ.) Mult Scler Relat Disord. 2024 Mar;83:105438 PMID: 38242052 SCOPUS ID: 2-s2.0-85183017643 01/20/2024
-
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
(Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G, Frexalimab Phase 2 Trial Group.) N Engl J Med. 2024 Feb 15;390(7):589-600 PMID: 38354138 02/14/2024
-
(Obeidat AZ.) Mult Scler Relat Disord. 2024 Feb;82:105389 PMID: 38118288 SCOPUS ID: 2-s2.0-85180351134 12/21/2023
-
(Abboud H, Subei A, Sengul B, Shin RK, Goulette P, Walch R, Coté J, Pace R, Obeidat AZ, Ferayorni L, Gholizadeh S.) Frontiers in Immunology. 2024;15 SCOPUS ID: 2-s2.0-85215693085 01/01/2024
-
Cardiac events in the setting of ofatumumab treatment: An association or A Co-incidence?
(Hamna Khan, Michelle Maynard, Ahmed Z Obeidat.) Neuroimmunology Reports. Khan, Hamna, Michelle Maynard, and Ahmed Z. Obeidat. Cardiac events in the setting of ofatumumab treatment: An association or A Co-incidence?. Neuroimmunology Reports 6 (2024): 100228. 12/01/2024